BC Partners and Bpifrance Acquire Biogaran from Servier

Groupe Berkem Acquires Biopress

April 3, 2023

Food & Beverage

Groupe Berkem completed the acquisition of Biopress, a French producer of 100% natural vegetable oils and plant proteins, effective April 1, 2023. The deal—carried out by Berkem Développement, a wholly owned subsidiary of Groupe Berkem—was paid in cash and funded from equity; Biopress's 11 employees joined the Group and the acquisition expands Berkem's local sourcing, processing capacity and access to agri-food, cosmetics, nutraceutical and industrial markets.

Servier Acquires Day One Biopharmaceuticals for About $2.5 Billion

March 6, 2026

Pharmaceuticals

Servier entered into a definitive agreement to acquire Day One Biopharmaceuticals, a commercial-stage biopharmaceutical company, in a cash deal valued at about $2.5 billion. Servier will pay $21.50 per share and expects the transaction to close in the second quarter of 2026, subject to customary regulatory approvals and tender conditions.

Keensight-backed Biovian and 3P Biopharmaceuticals Merge to Form 3PBIOVIAN

February 1, 2024

Biotechnology

Biovian and 3P Biopharmaceuticals have combined under their common shareholder Keensight Capital to form 3PBIOVIAN, a pan‑European biologics CDMO offering end‑to‑end development and manufacturing across microbial and mammalian protein expression, viral vectors, cell therapy and plasmid DNA. The combined group will operate sites in Pamplona‑Noáin (Spain) and Turku (Finland), maintain a commercial office in Boston, and employ over 500 professionals with gross sales above €75m; ERES IV (advised by Elyan Partners) and Sodena will remain minority shareholders alongside Keensight.

Partners Group Acquires Pharmathen from BC Partners

July 19, 2021

Pharmaceuticals

Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.

Pharmaron Acquires 82.54% of Biortus Biosciences

October 28, 2025

Healthcare Services

Pharmaron Beijing Co., Limited has entered into a definitive Share Purchase Agreement to acquire 82.54% of Biortus Biosciences Co., Ltd. and its affiliates. The transaction is expected to close after satisfaction of customary closing conditions and is intended to strengthen Pharmaron’s structure-based drug discovery and protein science capabilities.

Stifel Financial to Acquire Bryan, Garnier & Co

January 7, 2025

Financial Services

Stifel Financial has agreed to acquire Bryan, Garnier & Co., an independent full-service investment bank focused on European technology and healthcare companies. Financial terms were undisclosed, and the deal is positioned as a complementary expansion of Stifel’s global advisory capabilities and vertical focus.